Roivant saw price target increases from Citi ($26) and H.C. Wainwright ($23) following their Q2 report. The timeline for major catalysts has shifted heavily to 2026. Batoclimab Phase 3 data is now expected in the first half of 2026, and the Moderna litigation trial is scheduled for March 2026. The brepocitinib NDA filing is also set for early 2026. Analysts generally see the schedule changes as strategic choices rather than performance issues, but it pushes the proof points further out.